News briefing: Small merger to advance anti-aging program; Sanger Institute spinout nabs $50M from Series C
Small-cap player Akers Biosciences $AKER has engineered a reverse merger with private company MyMD Pharmaceuticals.
The new combined biotech, which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
